Method for producing cordyceps sinensis Qisheng capsule preparation

A production method and technology of Cordyceps, which are applied in the directions of capsule delivery, pharmaceutical formulations, and medical preparations containing active ingredients, can solve the problems of easy rejection, single production method, loss of active ingredients, etc., and achieve a simple and feasible production method. The effect of reducing energy consumption and avoiding the loss of ingredients

Active Publication Date: 2017-05-31
XIANGYU PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The applicant found in the pharmaceutical process that the production method of the drug is relatively simple, and the same extraction process is used for various raw materials, so there is a defect in the lo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0020] Example 1

[0021] The production method of Cordyceps Qishen capsules includes the following steps:

[0022] 1) Weigh the raw materials according to the weight portion for use: 80g Cordyceps, 1200g Astragalus, 600g Salvia, 600g Safflower, 320g Suanzaoren;

[0023] 2) Take the Cordyceps sinensis and crush it into fine powder;

[0024] 3) Take the astragalus, crush it, pass a 100-mesh sieve, place it in a container, add double weight of 85% (v / v) ethanol, stir and extract at 300rpm, control the microwave power to 500W during the extraction process, and the extraction time to 120min; Then place it at 4°C for 8 hours, filter, and filter the residue for use; the filtrate is evaporated under reduced pressure to recover ethanol, and the filtrate is concentrated to extract A with a density of 1.2g / ml; the content of astragaloside IV in extract A is tested by high performance liquid chromatography 1.31mg / ml;

[0025] Add twice the weight of the filter residue to the above filter residue...

Example Embodiment

[0039] Example 2

[0040] Animal toxicity test

[0041] There were 40 healthy Kunming mice, half male and half male, and weighed 18.6±2.1g. The 40 mice were randomly divided into two groups, each group was half male and half male, and 20 of them served as a control group and were irrigated with normal water; Mice were given the preparation of Example 1 at a dose of 200 mg / kg three times a day. Toxicity experiments on mice showed that: Compared with the control group, there was no significant difference in mice after administration. The experiment was observed for two consecutive weeks. The general condition, food intake, drinking water, and weight gain were normal. On the day of administration and within two weeks after administration, no animal deaths were seen, indicating that the drug has low toxicity and is safe for clinical use.

Example Embodiment

[0042] Example 3

[0043] Comparison test of efficacy

[0044] Animals: 80 SD male rats, weighing 219±13g, healthy and clean, raised in the company's experimental animal center.

[0045] Grouping treatment: 80 SD male rats were randomly selected as the blank control group based on no significant difference in body weight, and the remaining 60 rats were prepared for adriamycin nephropathy model. The model rats were randomly divided into model control group (gavage of normal saline, dose 100mg / kg), Example 1 group (gavage of the preparation produced in Example 1, dose 100mg / kg), control group 1 (gavage control The preparation produced in Example 1, with a dose of 100 mg / kg), with 20 animals per group. Gavage once a day for one month. Rats in each group were left with 24h urine volume at the beginning and end of the experiment to measure the quantification of 24h urine protein (Sullic acid method).

[0046] Observation indicators: including the rat's diet, body hair, stool, mental sta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Uv intensityaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of Chinese medicinal herb extraction and discloses a method for producing a cordyceps sinensis Qisheng capsule preparation. The method comprises the following steps: 1) weighing raw materials; 2) preparing cordyceps sinensis fine powder; 3) preparing astragalus extract; 4) preparing radix salviae milliorrhizae extract; 5) preparing safflower extract; 6) preparing spine date seed extract; and 7) uniformly mixing, grinding and granulating. The preparation produced by the invention has an excellent effect of treating chronic nephritis, and the effect is superior to that of the existing cordyceps sinensis Qisheng capsule product.

Description

technical field [0001] The invention belongs to the technical field of Chinese herbal medicine extraction, and in particular relates to a production method of a capsule preparation of Cordyceps Qishen. Background technique [0002] Cordyceps Qishen Capsule is an effective drug for treating chronic nephritis. Its ingredients are relatively simple, its effect is good, and its side effects are small, so it is favored by patients. The applicant found in the pharmaceutical process that the production method of the drug is relatively simple, and the same extraction process is used for various raw materials, which has the defect of loss of active ingredients, and the Cordyceps Qishen Capsules need to be taken 4 capsules each time, three times a day, and the dosage is too large , some patients are difficult to accept, prone to rejection. How to maximize the utilization of raw materials and improve drug efficacy by improving the process is a problem that we need to study. Contents...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/725A61K9/48A61P13/12
CPCA61K9/48A61K36/068A61K36/286A61K36/481A61K36/537A61K36/725A61K2236/19A61K2236/331A61K2236/333A61K2236/39A61K2236/53A61K2300/00
Inventor 林凡儒聂昌盛付君叶毛传伟杜玲杰
Owner XIANGYU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products